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Abstract
Cerebral cavernous malformations (CCMs) are vascular lesions predominantly developing
in the central nervous system (CNS), with no effective treatments other than surgery. Loss-
of-function mutation in CCM1/krev interaction trapped 1 (KRIT1), CCM2, or CCM3/pro-
grammed cell death 10 (PDCD10) causes lesions that are characterized by abnormal vas-
cular integrity. Vascular endothelial cadherin (VE-cadherin), a major regulator of endothelial
cell (EC) junctional integrity is strongly disorganized in ECs lining the CCM lesions. We
report here that microRNA-27a (miR-27a), a negative regulator of VE-cadherin, is elevated
in ECs isolated from mouse brains developing early CCM lesions and in cultured ECs with
CCM1 or CCM2 depletion. Furthermore, we show miR-27a acts downstream of kruppel-like
factor (KLF)2 and KLF4, two known key transcription factors involved in CCM lesion devel-
opment. Using CD5-2 (a target site blocker [TSB]) to prevent the miR-27a/VE-cadherin
mRNA interaction, we present a potential therapy to increase VE-cadherin expression and
thus rescue the abnormal vascular integrity. In CCM1- or CCM2-depleted ECs, CD5-2
reduces monolayer permeability, and in Ccm1 heterozygous mice, it restores dermal vessel
barrier function. In a neonatal mouse model of CCM disease, CD5-2 normalizes vasculature
and reduces vascular leakage in the lesions, inhibits the development of large lesions, and
significantly reduces the size of established lesions in the hindbrain. Furthermore, CD5-2
limits the accumulation of inflammatory cells in the lesion area. Our work has established
that VE-cadherin is a potential therapeutic target for normalization of the vasculature and
highlights that targeting miR-27a/VE-cadherin interaction by CD5-2 is a potential novel ther-
apy for the devastating disease, CCM.
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Introduction
Cerebral cavernous malformations (CCMs) are vascular malformations mostly occurring in the
central nervous system (CNS) [1]. CCM lesions are formed by abnormal dilated blood capillaries.
One of the key features of CCM is the existence of gaps between endothelial cells (ECs) lining the
lesions [2], which are leaky and can cause hemorrhagic stroke and seizure [3–5]. Currently, there
is no treatment for CCMs other than surgery, which is limited by size and depth of the lesions.
Familial CCMs in humans are a result of loss-of-function mutation in either one of three
genes, CCM1 (krev interaction trapped 1 [KRIT1]), CCM2, and CCM3 (programmed cell
death 10 [PDCD10]) [6]. Mice with postnatal loss of Ccm genes in ECs develop similar brain
vascular lesions as seen in human CCM patients. In both humans and mice, loss of CCM1 or
CCM2 leads to similar defects in vascular integrity, morphology, and burden of CCM lesions,
with CCM3 deletion giving a more severe phenotype [7–10].
The molecular pathways involved in CCM development include the kruppel-like factor
(KLF)2/4 pathway, endothelial-to-mesenchymal transition, RhoA/ROCK/phospho myosin
light chain (pMLC), and, more recently, toll-like receptor 4 (TLR4) signaling through gut
microbiome composition [3,9,11–14]. Although the clinical course of CCM disease is highly
variable, a common feature is the disruptive EC–EC junctions and enhanced permeability
[2,4,11,15], which likely explains the hemorrhage and inflammatory response in CCMs. Con-
sistent with this, key endothelial junction molecules, including vascular endothelial cadherin
(VE-cadherin), zonula occludens-1 (ZO-1), and claudin-5, are decreased or disorganized in
lesions [10,16]. VE-cadherin, the ‘hub’ of EC junctional molecules, regulates the actin cytoskel-
eton through RhoA [17]. It also functions upstream of claudin-5, a key protein in tight junc-
tions in the CNS [18,19]. In addition, VE-cadherin is a critical endothelial regulator of
transforming growth factor-β (TGF-β) signaling [20]. Thus, VE-cadherin serves as an appeal-
ing target for CCM, since RhoA, claudin-5, and TGF-β are all deregulated in this disease
[9,11,12,21] and are linked to disruption of vascular integrity. Therapies that increase the
expression of VE-cadherin could restore vascular integrity and have a profound impact on
CCM disease [22]. Indeed, the RhoA kinase inhibitors fasudil and, to a lesser extent, simva-
statin decreased CCM lesions through restoring vascular integrity in mice [9,23].
MicroRNAs are key regulators of gene expression and play important roles in regulation of
vascular integrity [24]. We previously showed microRNA-27a (miR-27a) targets VE-cadherin
to disrupt vascular integrity [25,26]. Herein, we show miR-27a is overexpressed in brain ECs
isolated from mice with CCMs. CD5-2 is a 15-nt-long target site blocker (TSB), which binds to
the miR-27a binding site in the VE-cadherin 30 UTR [25,26]. We previously showed CD5-2
increases endogenous VE-cadherin expression and restores vascular integrity in retinopathy,
in peripheral ischemic vessels, and cancer vessels [25–27]. Based on this knowledge, we pro-
pose a strategy to treat CCMs through restoring VE-cadherin expression. We demonstrate
here that the miR-27a/VE-cadherin interaction is CCM relevant and can be targeted by CD5-2
to normalize the vasculature of CCM lesions, resulting in decreased inflammation and inhibi-
tion of CCM pathologies. These data highlight VE-cadherin as a druggable target in diseases
with abnormal vascular integrity.
Results
Up-regulation of microRNA-27a in the context of abnormal VE-cadherin
expression in CCM pathology
Disruption of EC junctions and abnormal vascular integrity are key features in CCM pathol-
ogy [9,11]. In the lesions of human patients with CCM, VE-cadherin expression is disrupted
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compared with its expression in normal vessels (Fig 1A). In a neonatal mouse model of CCM
disease (the EC specific Ccm2 deleted model, Ccm2ECKO), numerous CCM lesions appeared in
the eye (S1A Fig) and hindbrains (S1B Fig) [3,21]. Furthermore, depletion of CCM1 or CCM2
in both primary human umbilical vein endothelial cells (HUVECs) and brain microvascular
EC line, hCMEC/D3, using small interfering RNA (siRNA), resulted in decreased mRNA
expression of key junctional molecules such as VE-cadherin and claudin-5 (S2A and S2B Fig)
[28], and disruption of EC junctions, as shown by VE-cadherin staining (S2C Fig).
MicroRNAs play an important role in the regulation of vascular integrity [29]. A number of
microRNAs were significantly regulated in CCM2-depleted ECs (Fig 1B), including miR-27a
and miR-125a. MiR-27a targets VE-cadherin, and its enhanced expression results in loss of bar-
rier integrity and induction of vascular leak [26]. In contrast, miR-125a is required for brain EC
barrier formation [30]. Brain ECs extracted from Ccm1ECKO and Ccm2ECKO mice at 8 days post
birth (P8), when lesions are obvious, showed a small but significant increase in miR-27a but
decrease in miR-125a (Fig 1C). Indeed, this level is similar to that seen in vitro with CCM2
depletion mediated by siRNAs (Fig 1D). Even at P5, a time prior to the appearance of CCM
lesions, miR-27a shows a 25% increase in ECs from Ccm2ECKO mice (S2D Fig) [3]. In line with
our finding, a recent report shows miR-27a is the most up-regulated microRNA in the brain tis-
sues from human CCM patients [31], suggesting a potential role of miR-27a in CCM pathology.
Excessive expression of KLF2 and KLF4 are causal factors in CCM formation [3,14,32].
There are at least 3 putative KLF2/4 binding sites in the promoter of miR-27a, with two of
these conserved between human and mouse [33]. Knockdown of KLF2 or KLF4 by siRNA par-
tially inhibited the CCM2-depletion–induced miR-27a up-regulation in cultured ECs. Knock-
down of both KLF2 and KLF4 completely rescued miR-27a up-regulation (Fig 1D). In
addition, induction of the KLF2/4 pathway is independent of VE-cadherin, because KLF2 and
KLF4 are both up-regulated, with loss of CCM2 in VE-cadherin null ECs (Fig 1E). These data
implicate the presence of a regulatory pathway whereby loss-of-CCM up-regulates KLF2/4,
resulting in increased miR-27a, which may decrease VE-cadherin expression.
A TSB to miR-27a/VE-cadherin inhibits CCM pathogenesis
The data above suggest that blocking or preventing the negative regulation of miR-27a on VE-
cadherin may restore vascular integrity in CCM lesions and be beneficial for the treatment of
this disease. Because miR-27a has multiple targets besides VE-cadherin [34], targeting the
miR-27a itself raises the potential of off-targets effects [35]. TSB with enhanced stability and
specificity have been developed, which overcome this drawback by preventing the microRNA
from gaining access to the binding site on the 30 UTR of a specific target [36–44]. We devel-
oped CD5-2, a TSB that blocks the binding of miR-27a to its binding site specifically on VE-
cadherin 30 UTR (S3A Fig), leading to increased endogenous VE-cadherin expression, and reg-
ulates VE-cadherin–related pathways [25–27].
To explore the effect of CD5-2 in CCMs, we first confirmed CD5-2 was able to restore VE-
cadherin in CCM pathology. In cultured ECs with CCM1 or CCM2 depletion, CD5-2 rescued
the decreased expression of VE-cadherin and its key downstream target, claudin-5 [18] (S3B
Fig). In the animals with CCMs, CD5-2 was given via intraperitoneal (IP) injection on P6,
when the earliest lesions had just started to form (S4A Fig) [3], and again on P8. Consistent
with the in vitro data, when assessed at P12 (S4A Fig), injection into Ccm2ECKO mice resulted
in a significant increase in VE-cadherin expression in the EC lining of some CCM lesions (Fig
2Ai), whereas other lesions show improved VE-cadherin localization in the junction area (Fig
2Aii). In situ assay confirmed that CD5-2 localized into the brain vessels within 6 hours after
IP injection to the Ccm2ECKO mice at P6 (Fig 2B). ZO-1 is another key tight junction molecule
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in the maintenance of brain vascular integrity. In normal brain vessels, ZO-1 localizes to the
junctions (S4Bi Fig). Although CD5-2 increases ZO-1 expression levels, it is not seen in the
junctional area (S4Bii Fig).
Fig 1. VE-cadherin and miR-27a are down-regulated and up-regulated in CCMs, respectively. (A) Representative
immunohistochemistry staining of VE-cadherin of human lesion-free and CCM brain tissue. Arrowheads, VE-
cadherin; dashed line, vascular lumen of CCM lesions. Bar, 100 μm (n = 6). (B) Real-time PCR measurement of
microRNA expression in HUVECs treated with siRNA negative control (si-Ctrl) or siRNA to CCM2 (n = 3–4). (C)
miR-27a was up-regulated and miR-125 was down-regulated in ECs isolated at P8 mice. RNA were from two separate
preparations. The first includes the following: WT (n = 5), Ccm1ECKO (n = 3), and Ccm2ECKO (n = 2) mice. The second
includes the following: WT (n = 4), Ccm1ECKO (n = 3), and Ccm2ECKO (n = 2) mice. (D) siRNA knockdown of KLF2 or
KLF4 or both in HUVECs blocks loss-of-CCM2–induced expression of miR-27a (n = 3–4). (E) Measurement of KLF2
and KLF4 in VE-cadherin null ECs with CCM2 depleted by siRNAs (n = 3). Data represent mean ± SEM; �P< 0.05,
��P< 0.01 determined by one-way ANOVA with Tukey correction. For the raw data used for quantification, see Fig 1
in S1 Data. CCM, cerebral cavernous malformation; EC, endothelial cell; HUVEC, human umbilical vein endothelial
cell; KLF2, kruppel-like factor 2; miR-27a, microRNA-27a; siRNA, small interfering RNA; VE-cadherin, vascular
endothelial cadherin; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3000734.g001
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CD5-2 also significantly reduced the vascular lesion burden, as shown for 3 representative
mice (Fig 3A). Lesion size was firstly assessed morphologically in hindbrain sections by hema-
toxylin–eosin (HE) staining and by CD31 staining (S4C and S4D Fig). To precisely quantitate
CCM lesions, we imaged P12 hindbrains using contrast-enhanced, high-resolution X-ray
micro–computed tomography (microCT) and measured lesion volumes using semiautomated
software [3,8]. Treatment of Ccm2ECKO mice with CD5-2 conferred a significant reduction
(Fig 3B) with around 60% inhibition in both total CCM lesion volume and on the size of the
large lesions (Fig 3Ci-iv). In addition, there was a trend for CD5-2 to reduce the total lesion
numbers, although the difference was not statistically significant (Fig 3D). However, when the
lesions were classified into three groups according to their size, CD5-2 significantly reduced
the large (>10−2 mm3) and medium (10−3–10−2 mm3) lesions but not the small (<10−3 mm3)
lesions (Fig 3E). Large lesions are more likely to have abnormal EC junctions, shown by dis-
continuous VE-cadherin staining (S1Bii Fig). The lesion size is correlated with vascular leak
Fig 2. CD5-2, a TSB to miR-27a/VE-cadherin, can be delivered to brain vasculature and regulates VE-cadherin.
(A) (i) CD5-2 increased VE-cadherin expression in CCM lesions from mouse samples given the control drug (Ctrl) or
CD5-2. (ii) CD5-2 improves VE-cadherin localization in CCM lesions compared with mice given the control drug
(Ctrl). In Ctrl, the white arrows point to disruptive VE-cadherin staining. In CD5-2, the red arrows point to junctional
VE-cadherin. (B) In situ detection of CD5-2 in the blood vessels in the hindbrain of P6 Ccm2ECKO animal, 6 hours after
IP injection of CD5-2. The image without CD5-2 probe was used as background control (top). CD5-2 was detected as
the color of cyan (bottom) with ECs stained with CD31. Bar, 50 μm (left); 10 μm (right). Values are shown as
mean ± SEM, ��P< 0.01, determined by Student t test. For the raw data used for quantification, see Fig 2 in S1 Data.
CCM, cerebral cavernous malformation; EC, endothelial cell; IP, intraperitoneal; miR-27a, microRNA-27a; TSB, target
site blocker; VE-cadherin, vascular endothelial cadherin.
https://doi.org/10.1371/journal.pbio.3000734.g002
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susceptibility and reflects the severity of CCM disease [21,45]. Of note, the larger CCM lesions
in humans are those that are more prone to hemorrhage, which therefore are more likely to
need surgical intervention [23].
To further establish the therapeutic potential of CD5-2, we investigated whether it is able to
affect established lesions—especially the large lesions. To address this possibility, we treated
mice at P12 and P14 and brains were dissected and assessed at P19 (S5A Fig). This is the time
Fig 3. CD5-2 rescues CCM lesions in the hindbrain of Ccm2ECKO mice. (A) Visual appearance of CCM lesions in the hindbrain of
representative three P12 Ccm2ECKO mice treated with control or CD5-2. Bar, 1 mm. (B) Composite microCT images of the same
hindbrains shown in (A). Bar, 1 mm. CCM lesions are shown in red. (C) Quantitation of CCM lesion by (i) total lesion volume and (ii) the
largest lesion volume, and (iii) the mean value of the largest 5 or (iv) 20 lesions. (D) Quantitation of lesion number. Ctrl, 186.6 ± 26.31;
CD5-2, 127.3 ± 18.44. (E) Lesions were classified into three groups according to volume size (large:>10−2 mm3; medium: 10−3–10−2 mm3;
small:<10−3 mm3). Large, Ctrl: 12.9 ± 1.6; CD5-2: 5.6 ± 1.3; medium, Ctrl: 39 ± 4.9; CD5-2: 26.3 ± 3.5; small, Ctrl: 134.7 ± 24.0; CD5-2:
95.1 ± 15.4, n = 7 mice for control-treated group (Ctrl) and n = 9 mice for CD5-2–treated group. Mice are from 4 different litters. Values
are shown as mean ± SEM, N.S, not significant, �P< 0.05, ��P< 0.01, ���P< 0.001, determined by Student t test. For the raw data used
for quantification, see Fig 3 in S1 Data. CCM, cerebral cavernous malformation; Ctrl, control; microCT, micro–computed tomography.
https://doi.org/10.1371/journal.pbio.3000734.g003
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frame when most of the CCM lesions are established with numerous large lesions, as is seen in
Fig 4A [21]. CD5-2 was able to significantly reduce the volume of CCM lesions in the brain
(Fig 4A and 4B). Although, as before, CD5-2 did not affect overall lesion numbers (S5B Fig), it
significantly reduced the number and size of the very large, the large, and the medium sized
lesions (Fig 4C and 4D).
Fig 4. CD5-2 decreases established CCM lesions in the hindbrain of Ccm2ECKO mice and lesions in the retina of Ccm2ECKO mice. (A)
Visual appearance of CCM lesions in the hindbrains of three representative P19 Ccm2ECKO animals treated with control or CD5-2. Bar, 1
mm. (B) microCT images of the hindbrains from two mice shown in (A). CCM lesions are shown in red. (C) Quantitation of CCM lesion
volume (normalized to 1.0 for mice that received control) by total lesion volume and mean size of the largest 5 lesions. (D) Number of
lesions per brain within different size ranges. In (C-D), n = 4 mice for control-treated group and n = 4 mice for CD5-2–treated group.
Mice are from 4 different litters. (E) Representative images of whole mount retina isolated from control- and CD5-2–treated littermates
stained with isolectin-B4. Mice were treated at P6 and P8. Retinas were dissected at P12. Images are representative of 6 retinas from 3 mice
(3 litters) for each treatment. Bar, 200 μm. Quantification is given as the percentage of the marked condensed vascular plexus at the leading
edge against the total area of the retinal vasculature. (F) Mice were treated at P8 and P12. Retinas were dissected at P19. Images are
representative of 10 retinas from 5 mice (3 litters) for each treatment. Bar, 200 μm. Values are shown as mean ± SEM. �P< 0.05,
��P< 0.01, ���P< 0.001, determined by Student t test. For the raw data used for quantification, see Fig 4 in S1 Data. CCM, cerebral
cavernous malformation; microCT, micro–computed tomography.
https://doi.org/10.1371/journal.pbio.3000734.g004
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In the retinas of Ccm2ECKO mice, venous malformations developed at the periphery of vas-
cular plexus, as visualized by isolectin-B4 staining (S1A Fig) and as previously reported
[11,21]. In both early- (P6 and P8) and late-stage (P12 and P14) treated animals, CD5-2 inhib-
ited the lesions in the retina (Fig 4E and 4F). Importantly, CD5-2–treated wild-type (WT) ani-
mals showed no noticeable differences in the brain and retina, or total hindbrain volume at
P12 and P19 (S6A–S6C Fig). Overall, these results suggest that CD5-2 is able to increase VE-
cadherin expression and rescue CCM lesion in mice with CCM disease.
CD5-2 normalizes vasculature and blocks vascular leakage in CCM lesions
VE-cadherin plays a central role in the regulation of vascular integrity. We next investigated
whether CD5-2 altered the integrity of the endothelium in CCM pathology. Images taken by
scanning electron microscope (SEM) show that CD5-2–treated animals have improved vascu-
lar integrity with clear EC junctions and a flattened morphology indicative of nonactivated
cells and normalized endothelium (Fig 5A). Consistently, a single treatment of CD5-2
markedly prevented vascular leakage of the lesions, as measured by the amount of cadaverine
that leaked from blood vessels into brain parenchyma (11) (Fig 5B). Notably, these in vivo
findings are in line with the inhibition of fluorescein isothiocyanate (FITC)-dextran passing
through the EC monolayer after CD5-2 treatment that we observed in ECs in vitro (Fig 5C),
suggesting CD5-2 has a direct effect on improving EC junction. Furthermore, Ccm1 heterozy-
gous mice (Tie2Cre, Ccm1fl/+) exhibit increased basal vascular leak and stronger response to
vascular endothelial growth factor (VEGF) [9]. CD5-2 restores the dermal vessel integrity
under both basal conditions and after VEGF stimulation (Fig 5D and S7 Fig). These results
suggested CD5-2 normalizes the vasculature in CCM pathology.
CD5-2 reduces RhoA but does not regulate KLF2/4
Increased RhoA/ROCK activity and excessive KLF2/4 are both drivers for CCM development
[12]. Further, RhoA/ROCK activation is linked with permeability regulation [46]. In the CCM1-
or CCM2-depleted ECs, CD5-2 directly rescued RhoA activity and decreased its downstream
pMLC, as visualized by immunofluorescence staining (S8A and S8B Fig). Although KLF2/4 over-
expression is critical for CCM development [3,14], CD5-2 had no effect on the expression of
KLF2/4, suggesting that its action may lie downstream of the induction of KLF2/4 (S8C Fig).
CD5-2 directly rescues inflammatory response via VE-cadherin
CCM lesions are also characterized by increased inflammation [11], which may contribute to
the disruption in vascular integrity in CCM pathology [47]. In animals with CCMs, intercellu-
lar adhesion molecule 1 (ICAM-1) expression, a key adhesion molecule involved in neutrophil
adhesion and transmigration, was inhibited in ECs lining the CCM lesions by the treatment of
CD5-2 (Fig 6A) [11]. In addition, there were significantly less CD11b-expressing inflammatory
cells associated with the vessel wall in the lesions of CD5-2–treated animals (S9A Fig) [11].
These results were consistent with the ability of CD5-2 to inhibit neutrophil migration into
inflamed tissue in the MC38 colon carcinoma, in which CD5-2 inhibited the number of
CD11b+/granulocyte (Gr)1hi in the solid tumor tissue. In combination with anti–programmed
cell death protein 1 (PD1), there was a further inhibition of the number of CD11b+/Gr1hi cells
in the tumor (S9B Fig).
To determine whether the action of CD5-2 is directly on the endothelium to inhibit inflam-
mation, we turned to in vitro studies. CCM1 or CCM2 depletion up-regulated ICAM-1
expression and increased activity of NF-κB, an essential transcription factor involved in
inflammation (Fig 6B and 6C) [48]. Treatment of the ECs with CD5-2 reversed these increases,
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Fig 5. CD5-2 normalizes CCM lesion structure in Ccm2ECKO mice. (A) Sample scanning electron micrographs of the
blood vessels in hindbrain from mice that received Ctrl (top) and CD5-2 (bottom). Images were taken from multiple
vessels. Two magnifications are shown: magnification 1, approximately 2,000×, bar: 10 μm; magnification 2,
approximately 5,000×, top bar: 5 μm, bottom bar: 2 μm (EC junctions are indicated by red arrow). (B) Hindbrains
photographed after fluorescent cadaverine injection. Bright-field (top) and fluorescence image with 555/60-nm
excitation and 610/75-nm emission (bottom). An animal without cadaverin Alexa 555 injection was used as the
background (i,ii); fluorescence from control (Ctrl) and CD5-2 treated animals was measured by stereomicroscope (iii-
vi) and quantified by Fiji imageJ software (vii). Ctrl n = 5; CD5-2 n = 4 from 2 litters. Bar, 2 mm. (C) CCM1 or CCM2
in hCMEC/D3 was depleted by siRNAs. Cells were then transfected with control (Ctrl) or CD5-2. Endothelial
monolayer permeability to FITC-dextran (40 KDa) was determined by measurement of absorbance at 490 nm (A490)
(n = 2–3). (D) Miles assay of dermal permeability in heterozygous Ccm1 (Tie2-Cre, Ccm1 fl/+) mice in response to PBS
or VEGF after pretreatment with control or CD5-2 (n = 6). Values are shown as mean ± SEM. ��P< 0.01,
���P< 0.001, ����P< 0.0001, determined by Student t test or one-way ANOVA with Tukey correction. For the raw
data used for quantification, see Fig 5 in S1 Data. CCM, cerebral cavernous malformation; EC, endothelial cell; FITC,
fluorescein isothiocyanate; hCMEC/D3, human cerebral microvascular endothelial cell line; siRNA, small interfering
RNA; VEGF, vascular endothelial growth factor.
https://doi.org/10.1371/journal.pbio.3000734.g005
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Fig 6. CD5-2 inhibits inflammatory response in CCM lesion via VE-cadherin. (A) CD5-2 effects on ICAM-1
expression in CCM lesion. Sections were triple-stained for DAPI (blue) or CD31 (green), ICAM-1 (red); 3 mice were
utilized for each condition. Representative sections are shown. Bar, 8 μm. (B-C) Western blot analysis of ICAM-1 (B)
and phospho-p65 (C) in brain microvascular ECs (hCMEC/D3) treated with 10 nM siRNAs for scramble control
(Ctrl), CCM1, or CCM2 for 4 hours, followed by transfection of 15 nM CD5-2 or controls then cultured overnight.
Molecular weights in kilodaltons are shown. ICAM-1 antibody (Cell signalling #4915) gave two bands (89 and 92 kDa).
This antibody recognizes the ICAM-1 C-terminal portion, which is dense with ubiquitination and phosphorylation
sites and, as such, #4915 can detect multiple sized ICAM moieties. Representative blots are shown (n = 3) with α-
tubulin or β-actin rabbit used as loading control. (D) Representative images of dynamic adhesion of neutrophils to
control- or CD5-2–treated ECs following the stimulation with TNF-α for 4 hours. Quantification of number of
adherent neutrophils with control or CD5-2–treated ECs is given (n = 3). (E) Representative images of paracellular
transmigration of neutrophils (green) through TNF-α–stimulated endothelium (VE-cadherin, red) in the presence of
control and CD5-2 in vitro. Transmigrated neutrophils appear GFPdim. (F) (i) Heatmap of all genes between control
(Ctrl) and CD5-2 (CD5-2) in VE-cadherin–expressing ECs (VE-cadherin+/+). (ii) GSEA analysis of differentially
expressed genes (DEGs) between Ctrl- and CD5-2–treated ECs. (iii) Bar plot of selected inflammation-related DEGs
inhibited by CD5-2. Values are shown as mean ± SEM. �P< 0.05, ��P< 0.01, N.S, not significant, determined by
Student t test or one-way ANOVA with Tukey correction. For the raw data used for quantification, see Fig 6 in S1
Data; Fig 6B and 6C in S1 Raw images. CCM, cerebral cavernous malformation; CD31, cluster of differentiation 31;
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suggesting a direct inhibition on the inflammatory response in ECs (Fig 6B and 6C) [11,49,50].
Furthermore, CD5-2 pretreatment of the endothelium inhibited both neutrophil adhesion and
transmigration across the EC monolayer, two key steps involved in inflammation [51,52].
Using a model of neutrophil adhesion under flow (shear stress is 2 dyns/cm2), tumor necrosis
factor-α (TNF-α) stimulation increased the number of adherent neutrophils in control-treated
ECs, as expected [53]. In contrast, prior treatment of the ECs with CD5-2 resulted in a signifi-
cant reduction in the number of adherent neutrophils (Fig 6D and S1 Movie). In addition,
CD5-2 inhibited the transmigration of neutrophils across the endothelium, as ascertained by
using a transwell migration assay (S9C Fig). To visualize the process of neutrophil transmigra-
tion in vitro, we used live cell fluorescent imaging. Neutrophils were labelled with CellTrack
Green and allowed to transmigrate through TNF-α–stimulated ECs that had been treated
either with control or CD5-2. As shown in S2 Movie and in Fig 6E, neutrophils preferentially
transmigrated via the paracellular route, and CD5-2 significantly inhibited transmigration of
neutrophils (transmigrated cells appear green fluorescent protein [GFP]dim).
We have previously investigated the specificity of the CD5-2 against 2 other miR-27–veri-
fied targets, semaphoring 6A (SEMA6A) and peroxisome proliferator-activated receptor
gamma (PPARγ) [26]. In addition, when the 1,166 predicted targets for miR-27a were ana-
lyzed for complementarity to CD5-2, the closest match still displayed 2 out of 15 oligonucleo-
tide mismatches and therefore is unlikely to be a target. Thus, CD5-2 shows high selectivity for
VE-cadherin as the target.
RNA sequencing (RNA-seq) has been used to identify VE-cadherin–mediated downstream
signaling [54]. To further confirm CD5-2 works through VE-cadherin, we applied RNA-seq–
based transcriptomic analysis to control- or CD5-2–treated ECs with or without VE-cadherin
expression. In ECs with VE-cadherin expression (VE-cadherin+/+), the results show 585 differ-
entially expressed genes (DEGs) in CD5-2–treated ECs compared with control-treated ECs
(P< 0.05; false discovery rate [FDR]� 0.005, Fig 6Fi). The Gene Set Enrichment Analysis
(GSEA) revealed CD5-2 significantly down-regulated the gene sets involved in neutrophil
arrest/transmigration pathways such as extracellular matrix (ECM) receptor interaction [55],
focal adhesion [56], platelet homeostasis [57], and platelet-derived growth factor (PDGF) sig-
nalling [58] (Fig 6Fii). In addition, down-regulated DEGs also included some highly expressed
genes that were not uncovered by GSEA but have been reported to be involved in neutrophil
arrest/transmigration, including Notch homolog 1 (Notch1) [59,60], endoglin (ENG) [61], a
disintegrin and metalloproteinase with thrombospondin motifs 7 (ADAMTS7) [62], and leu-
kocyte receptor cluster member 8 (LENG8) [63] (Fig 6Fiii). ECs without VE-cadherin expres-
sion (VE-cadherin null ECs: VE-cadherin−/−) express miR-27a (Ct value is approximately 29
when measured in 10-ng tRNA by real-time PCR). In stark contrast to expression seen in nor-
mal ECs, in VE-cadherin−/− ECs, no gene was significantly differently expressed between the
control- and CD5-2–treated groups when using the same cutoff criteria (S10 Fig), suggesting
VE-cadherin is essential for the CD5-2–mediated gene changes [64].
Discussion
VE-cadherin is critical in the maintenance of vascular integrity [65], and abnormal VE-cad-
herin expression is seen in CCMs [28,66] (Figs 1A and 2B). The work herein describes VE-
EC, endothelial cell; GFP, green fluorescent protein; GSEA, Gene Set Enrichment Analysis; hCMEC/D3, human
cerebral microvascular endothelial cell line; ICAM-1, intercellular adhesion molecule 1; NF-κB, nuclear factor kappa B;
PDGF, platelet-derived growth factor; siRNA, small interfering RNA; TNF-α, tumor necrosis factor-α; TSB, target site
blocker; VE-cadherin, vascular endothelial cadherin.
https://doi.org/10.1371/journal.pbio.3000734.g006
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cadherin as a valid therapeutic target for restoration of integrity and normalization of the vas-
culature in CCM development. To date, there have been limited ways of increasing the levels
of an endogenous gene. We show that CD5-2, a microRNA TSB preventing miR-27a/VE-cad-
herin interaction, restores the levels and localization of VE-cadherin in the endothelium of
CCM lesions, leading to inhibition of associated inflammation and lesion development. Our
results provide an innovative therapeutic strategy for CCMs.
There are three striking observations concerning the effect of blocking miR-27a/VE-cad-
herin interaction by CD5-2 on CCM lesion development. Firstly, CD5-2 is able to inhibit the
total volume of lesions especially the size of the large lesions in Ccm2ECKO mice, indicating that
CD5-2 is able to inhibit lesion growth. Secondly, CD5-2 showed strong inhibition on estab-
lished large lesions and suggests CD5-2 may promote the regression of the lesion, or at least be
able to stabilize established lesions and to inhibit their growth throughout the time frame of
the experiment. At present, there is no technique available to give the resolution and sensitivity
that would allow the analysis of the progression of individual lesions over the time period of
the experiment. The fact that CD5-2 showed strong inhibition on both the number and size of
the established large lesions would suggest that it, or other small molecules that lead to
increased VE-cadherin expression and localization, may be therapeutically beneficial, because
large lesions have more severe disruptive inter-endothelial junctions, as shown by disorganized
VE-cadherin staining, indeed, in humans, these are the lesions more likely to hemorrhage
[5,23]. Furthermore, lack of significant inhibition in the number of small lesions upon CD5-2
treatment suggests potentially that miR-27a/VE-cadherin may play a less important role in the
initiation of CCM development than in the growth of CCM lesions. KLF2/4 that acts upstream
of miR-27a, or thrombospondin 1 (TSP1), TLR4, and other unknown pathways, may initiate
CCM lesion development. The lack of effect on lesion number may also be due to the treat-
ment time frame of CD5-2. P6 is the time earliest lesions can be detected by immunohis-
tochemistry. A treatment regime earlier than P6 may be required for CD5-2 to prevent lesion
initiation.
In CCM lesion, CD5-2 treatment induces some vessels to show increased levels of VE-cad-
herin (Fig 2Ai) and some vessels to show improved EC junctional staining (Fig 2Aii). The dif-
ference in response to CD5-2 is not known at this stage, and we cannot relate these different
responses to the size of a lesion, which is subject to the shape of a lesion and where the lesion is
cut. CD5-2 also affects tight junctional molecules such as ZO-1. In normal vessels, ZO-1 is
junctional (S4Bi Fig), and although CD5-2 increases ZO-1 expression levels, little junctional
localization is evident (S4Bii Fig). Because tight junctions form after adherens junctions are
established [67], this may suggest that the junctions are still in the process of maturing. ZO-1,
together with is partner junctional adhesion molecule-A (JAM-A), acts as an essential unit for
tight junction assembly and regulation of the tension between ECs and barrier integrity [68].
Thus, together with our previous studies showing increases in Tie-2/protein kinase B (Akt)/
endothelial nitric oxide synthase (eNOS) signalling pathways in ECs [25], increased VE-cad-
herin expression and normalized localization induced by CD5-2 have profound effects to regu-
late the multiple pathways associated with junctional integrity.
The third noteworthy effect is the impact of CD5-2 on the inflammatory cell accumulation.
Inflammation is associated with increasing vascular permeability and infiltration of immune
cells, both key features of CCM lesions and both controlled by VE-cadherin [11,69,70]. On
one hand, CD5-2 inhibits vascular permeability, thus limiting a key aspect of the pathology
[5,10,11]. On the other hand, CD5-2 also significantly inhibited CCM depletion–induced
inflammation evidenced by decreased ICAM-1 and NF-κB activation in vitro and reduced
ICAM expression and numbers of CD11b+–expressing inflammatory cells associated with
lesions. The inhibition of neutrophil transmigration was recapitulated in a 2-cell system in
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vitro (Fig 6E), where only the endothelium is treated with CD5-2, thus strongly supporting the
effects of CD5-2 being mediated through ECs. Of note, paracellular transmigration of neutro-
phils requires transient junctional disassembly of EC junctions because they migrate between
adjacent cells, particularly through preexisting gaps at cell borders where three ECs meet [71].
In this study, we observed that neutrophils in the control group preferentially transmigrated
through the EC junctions, while CD5-2 significantly blocked this process. Interestingly, we
have previously observed CD5-2 exhibits selectivity on the inflammatory infiltrate, promoting
the CD8+ T-cell population of cells into tumors, whereas inhibiting neutrophils [25]. This is in
line with the role of normalized vasculature, which benefits the treatment of tumors [72].
Whether this selectivity exerts beneficial effects on the treatment of CCMs requires further
investigation.
Loss of CCM function results in enhanced KLF2/4 levels that are critical in CCM develop-
ment [3]. The role of KLF2/4 in CCM is interesting given that KLF2/4, especially KLF2, is
essential for proper vascular function [73,74]. This could be explained by the existence of a
critical protective range of KLF2/4 levels in various vascular beds. The level of expression of
KLF2/4 for each vascular bed may be linked to blood flow [48]. For example, in arterials,
KLF2/4 are normally highly expressed and associated with vascular stability and lack of inflam-
mation [74,75]. In diseases such as arteriovenous malformations (AVMs), Alk1 or ENG (two
key genes for AVMs) depletion induced higher-than-normal KLF2/4 expressions, and these
increased levels were non-protective [76]. In the brain capillary-venous system, where CCM
lesions develop, the ECs express the lowest levels of KLF2/4 in the human body (Gene expres-
sion for KLF2 ENSG00000127528.5, KLF4 ENSG00000136826.10, GTEx Analysis Release V7,
dbGaP Accession phs000424.v7.p2). Loss-of-function mutations of CCM genes result in
higher than normal expression of KLF2/4 for the capillary-venous system, and this increase is
associated with CCM development. We further show here that up-regulation of KLF2/4
induces miR-27a, leading to negative regulation of VE-cadherin expression and vascular integ-
rity. Intriguingly, miR-27a is also up-regulated in the plasma from patients with hereditary
hemorrhagic telangiectasia (HHT), a vascular malformation also characterized by abnormal
vascular integrity and fragile lesions [22,77]. Thus, miR-27a could be a common regulator of
vascular integrity, especially in the cerebral vascular system.
Collectively, our results confirm VE-cadherin as an important therapeutic target. Given
that miR-27a is increased in other diseases characterized by vascular leak [27] and in an
inflammatory environment [25], CD5-2 has potential to be therapeutically beneficial in a
broader stage than CCM. Our data suggest that the gene regulation induced by CD5-2 requires
VE-cadherin expression (S10 Fig). Considering the extensive downstream signalling linked to
VE-cadherin and, because miR-27 is also present in normal ECs, disturbing the equilibrium of
miR-27a and VE-cadherin expression could lead to increases of VE-cadherin in normal ECs.
Although lack of VE-cadherin has been shown to be harmful and has close links with diseases
[25,27,78], little evidence suggests that small levels of overexpression of VE-cadherin causes
any side effect. In addition, EC junctional molecules, including VE-cadherin, are tightly regu-
lated by many factors, including phosphorylation, dephosphorylation, and association with
other proteins [70]. MiR-27a may or may not be one of these regulatory factors in homeostasis.
The lack of major abnormalities in the cortical vascular density in WT animals treated with
CD5-2 (S6 Fig) supports the possibility that miR-27a may not be a major regulator in the qui-
escent vasculature. However, a thorough toxicity study of CD5-2 or any other small molecule
targeting VE-cadherin, as is required in preclinical development of a drug, would pave the way
for its application in clinic.
Finally, because multiple pathways are activated with loss of CCM function, combinations
with CD5-2 or alternate drugs that target VE-cadherin, together with drugs that are RhoA/
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ROCK [23], TSP1 [79], TLR4 [13] directed or targeting other miRNAs involved in vascular
integrity, such as miR-132 [80], may exert further additive or synergistic effects.
Materials and methods
Ethics statement
HUVECs were isolated from donated cords with approval from the Royal Prince Alfred Hospi-
tal Human Ethics Committee (permit and approval number X16-0225). The umbilical cords
were anonymous (donors nonidentifiable) and informed consent was given for their use. All
animal experiments were performed under protocols approved by the New South Wales Local
Sydney Health District Ethics Committees (permit and approval numbers 2013–029, 2017–
002, and 2017–028). All animal procedures conform to the guidelines from National Health
and Medical Research Council of Australia. All human samples from CCM patients were col-
lected and analyzed at Sun Yat-sen University, as approved by the Sun Yat-sen University Ethi-
cal Committee (permit and approval number SYSEC-KY-KS-2018-146). This study was
conducted in accordance with the Declaration of Helsinki.
Reagents and cells
The TSBs were synthesized by Axolabs (Kulmbach, Germany). Control TSB is similar in
sequence length and design to the TSB CD5-2, in terms of modifications and oligonucleotide
length. However, it has no homology to any known mouse, rat, or human miRNA or mRNA
sequence. The design and sequence of TSB control and CD5-2 were the same as published pre-
viously: CD5-2, 30-ACTTCGTUGACACUT-50; Control, 30-TCCAGAGATGGTUGA-50
[25,26]. Human cerebral microvascular EC line hCMEC/D3 was a gift from Dr. Georges Grau
(Bosch Institute, the University of Sydney) and maintained in Endothelial Cell Basal Medium-
2 (CC-3156, Lonza) supplemented by SingleQuots Kit (CC-4176, Lonza). HUVECs were iso-
lated and cultured as previously described [25,26] and used at passage 2. The umbilical cords
were anonymous (donors nonidentifiable), and informed consent was given for their use. VE-
cadherin null ECs were maintained in DMEM (11995065, Thermo Fisher Scientific, Waltham,
MA) with 10% FBS (Thermo Fisher Scientific, Waltham, MA).
Primary mouse cerebellar ECs were isolated as described previously [13]. MiniMACS separa-
tor and starting kit (130-090-312, Miltenyi Biotec, Bergisch Gladbach, Germany) were
employed for the isolation. In brief, brain microvascular fragments were dissected from control,
Ccm1ECKO, and Ccm2ECKO mice (P8). Each preparation was a pool of 2–5 mice. After digestion
[11], the cell pellet was passed through a sterile 70-μm Nylon mesh followed by centrifugation
(5 minutes, 300g). Cell pellets were incubated for 15 minutes at 4˚C with microbeads previously
coated with anti-CD31. Finally, ECs were separated by MS column in the MACS separator.
siRNA knockdown and drug treatments in cultured ECs
siRNAs were used for the knockdown experiments. For siRNA transfection, ECs were trans-
fected with siRNA against CCM1(s2510), CCM2(s38037), KLF2 (s20270), KLF4 (s17793), or
scrambled siRNA (4390843) with Lipofectamine RNAiMAX Reagent (13778150, all siRNAs
and reagents from Thermo Fisher Scientific, Waltham, MA) and then maintained overnight.
Culture medium was then changed. For co-transfection, siRNA transfection medium was
maintained for 4 hours. The second transfection with TSB CD5-2 or control was then per-
formed with HiPerFect Transfection Reagent (301705, Qiagen, Hilden, Germany) and main-
tained overnight as described before. Medium was changed to culture medium in the next day.
Cells were collected 24 or 48 hours after transfection for permeability assay or RNA/protein
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assay, respectively. siRNAs used were as follows: CCM1 (4390843, Thermo Fisher Scientific,
Waltham, MA), human CCM2 (s2510, Thermo Fisher Scientific, Waltham, MA), mouse
Ccm2 (s103626, s103627, s103628 Thermo Fisher Scientific, Waltham, MA), and scramble
(s38037, Thermo Fisher Scientific, Waltham, MA).
RNA and microRNA expression assay
Total RNA from freshly isolated mouse brain ECs was prepared with RNeasy micro kit (74004,
Qiagen, Hilden, Germany) according to the protocol. Total RNA from cultured ECs was iso-
lated by Trizol (15596018, Thermo Fisher Scientific, Waltham, MA), as previously reported
[29]. High-Capacity cDNA Reverse Transcription Kit (4368814, Thermo Fisher Scientific,
Waltham, MA) was used for cDNA synthesis. Real-time qPCR was performed with TaqMan
Gene Expression Master Mix (4369016, Thermo Fisher Scientific, Waltham, MA) or TaqMan
Universal PCR Master Mix (4324018, Thermo Fisher Scientific, Waltham, MA) using the spe-
cific TaqMan probe (432401, Thermo Fisher Scientific, Waltham, MA). Human probes used
were as follows: ACTIN (Hs01060665_g1), KRIT1/CCM1 (Hs01090981_m1), CCM2
(Hs01123855_m1), KLF2 (Hs00360439_g1), and KLF4 (Hs00358836_m1). Mouse probes used
were as follows: Actin (Mm00607939_s1), Krit1/Ccm1 (Mm01316552_m1), Ccm2
(Mm00524581_m1), Klf2 (Mm00500486_g1), and Klf4 (Mm00516104_m1). microRNAs used
were as follows: RNU6B (001093), RNU48 (001006), and miR-27a (000408). qPCR was per-
formed on a Biorad real-time PCR machine. The relative RNA and microRNA amount was
calculated with the 2−ΔΔCT method. β-actin was used as housekeeping control for gene expres-
sion assay. RNU48 or RNU6 small nuclear RNA is used as the reference gene for microRNA
expression measurement.
Western blotting
Proteins were isolated and quantified as described before [29]. Western blotting assay were
done according to the protocol from Invitrogen. In brief, equal amount of proteins were
loaded on NuPAGE 4%–12% Bis-Tris Protein Gels (Thermo Fisher Scientific, Waltham, MA),
and separated and transferred to PVDF membrane (polyvinyl difluoride, EMD Millipore, Bur-
lington, MA) by using Mini Gel Tank system (Thermo Fisher Scientific, Waltham, MA). After
being blocked with 5% skim milk in PBS-Tween 20 (0.05%), the PVDF membranes were incu-
bated with primary and HRP-linked secondary antibodies. Bands were visualized using ECL
or ECL Plus Western blotting Detection Reagents (GE Healthcare, Chicago, IL) on ChemiDoc
MP system (Bio-rad, Hercules, CA). Densitometric analysis was performed using Fiji imageJ
software (Version: 2.2.2-rc-34/1.50a, National Institutes of Health). The following antibodies
were used for Western blotting: VE-cadherin goat (1:1,000, sc-6458, Santa Cruz Biotechnol-
ogy, Dallas, TX), ICAM-1 rabbit (1:1,000, 4915, Cell Signaling Technology, Danvers, MA),
Phospho-NF-κB p65 rabbit (Ser536) (1:1,000, 3033, Cell Signaling Technology, Danvers, MA),
claudin-5 rabbit (1:1,000, sc-28670, Santa Cruz Biotechnology, Dallas, TX), α-Tubulin mouse
(1:1,000, T6074, Sigma-Aldrich, St. Louis, MO), and β-actin rabbit (1:1,000, A2103, Sigma-
Aldrich, St. Louis, MO). HRP-linked secondary antibodies: goat anti-mouse IgG HRP
(1:5,000, 10004302, Cayman Chemical, Ann Arbor, MI), goat anti-rabbit IgG HRP (1:5,000,
10004301, Cayman Chemical, Ann Arbor, MI), and donkey anti-goat IgG-HRP (1:5,000, sc-
2020, Santa Cruz Biotechnology, Dallas, TX).
RhoA activity assay
Measurement of active RhoA levels was determined using the GLISA assays (Cytoskeleton inc,
Denver, CO). Briefly, control, CCM1, or CCM2 siRNA–treated HUVECs were incubated for 1
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hour in serum-free medium 199, followed by incubation in medium with 1% serum overnight.
Cells were stimulated with TNF-α for 1 hour and lysed for the measurement of RhoA activity
according to the manufacturer’s protocol.
Transwell permeability assay in cultured ECs
For in vitro permeability assay, hCMEC/D3 cells were plated onto fibronectin-coated 3-μm-
pore transwell inserts (Corning Costar, Acton, MA). After 48 hours, 40-KDa FITC-conjugated
dextran (Sigma-Aldrich, St. Louis, MO) was added to the upper chamber, and medium was
taken from the lower chamber (20 μL) 20 minutes later. The amount of fluorescence was mea-
sured using a POLARstar Omega microplate reader (BMG Labtech, Ortenberg, Germany).
Induction of the neonatal CCM mouse model
Ccm1fl/+;Tg(Tie2-Cre), Cdh5-CreErt2, Ccm1fl/fl, and Ccm2fl/fl animals have been previously
described [8,12,13]. Cdh5-CreErt2;Ccm1fl/+ or Cdh5-CreErt2;Ccm2fl/+ were crossed with
Ccm1fl/fl or Ccm2fl/fl to generate Cdh5-CreErt2;Ccm1fl/fl (Ccm1ECKO) or Cdh5-CreErt2;Ccm2fl/fl
(Ccm2ECKO). To induce Ccm2 gene EC-specific deletion in neonatal mice, at P1, 40 μg of
4-hydroxytamoxifen (4OHT, Sigma-Aldrich, St. Louis, MO) dissolved in ethanol and corn oil
was injected intragastrically to pups.
Permeability in CCM neonatal animal
Permeability was measured as described previously with modification [11]. In brief, animals
(P6) first received Ctrl or CD5-2 treatment. After 2 days (P8), they received IP injection of
Alexa Fluor 555 cadaverine (Thermo Fisher Scientific, Waltham, MA) (25 μg per 1 g). Two
hours later, pups were euthanized by inhalation of CO2 and then underwent intracardiac per-
fusion with PBS. Brains were dissected immediately and fixed in 4% PFA at 4˚C overnight.
Fluorescence in the hindbrain was measured by M205FA stereomicroscope (Leica Biosystems,
Wetzlar, Germany) with a fluorescent lamp and filters for Cy3 (555/60 Ex and 610/75 Em).
Intensity of fluorescence was quantified by Fiji imageJ software (version 2.2.2-rc-34/1.50a,
National Institutes of Health).
Effect of CD5-2 on retinal vascular development
The retina vasculature was stained as described before [81]. In brief, retinas were equilibrated
with PBLEC (1 mM MgCl2, 1 mM CaCl2, 0.1 mM MnCl2, and 1% Triton X-100 in PBS) and
incubated with biotinylated isolectin-B4 (1:25, Vector Laboratories, Burlingame, CA) over-
night, washed, then incubated with streptavidin Alexa Fluor-594 (1:500, Thermo Fisher Scien-
tific, Waltham, MA) and mounted with ProLong Gold anti-fade reagent (Thermo Fisher
Scientific, Waltham, MA). Images were acquired using a Leica SP5 confocal microscope (Leica
Biosystems, Wetzlar, Germany). Lesions were marked as the areas of condensed vascular
plexus at the leading edge of the retinal vasculature. Fiji ImageJ software was used to quantify
vascular coverage of the whole retina and lesions.
VE-cadherin immunostaining in human CCM lesions
Surgical samples from human patients with CCM lesions were resected at Sun Yat-sen Univer-
sity. Normal-sized vessels (pseudonormal) present in samples from CCM patients were used
as internal control. Six patients (3 male, 3 female) between 25 and 52 years old were included
in this study. Tissue sections were paraffin-embedded and stained with rabbit anti–VE-cad-
herin (1:1,000, ab33168, Abcam,Cambridge, United Kingdom).
PLOS BIOLOGY Targeting VE-cadherin rescues cerebral cavernous malformations
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000734 June 5, 2020 16 / 27
IP TSB injection and organ dissection
TSB control and CD5-2 were administered to Ccm2ECKO neonatal CCM disease model. At P6
and P8 (early stage treatment) or P12 and P14 (late stage treatment), a 30 mg/kg dose of TSB
at 7.5 mg/mL dissolved in sterile nuclease free H2O was IP injected to Ccm2ECKO mice and WT
littermates. Pups were euthanized at P12 or P19 by inhalation of CO2 and then underwent
intracardiac perfusion with 2% paraformaldehyde (PFA, Sigma-Aldrich, St. Louis, MO) in 0.1
M PBS. Brains and eyes were dissected immediately and fixed in 4% PFA at 4˚C for down-
stream measurement.
Miles assay for assessment of dermal vascular leakage
Permeability in the skin was measured as previously reported [26,29]. In brief, the TSB inhibi-
tors or control were injected intradermally at 6 sites on the back of 8–20-week-old Ccm1fl/+;Tg
(Tie2-Cre) mice and WT littermates. After 24 hours, 200 μL of 0.5% Evans blue dye was
injected intravenously to animals. Thirty minutes later, PBS alone or PBS containing 100 ng of
VEGF-165 (R&D Systems, Minneapolis, MN) was injected intradermally into the same site as
the TSB inhibitors. After another 30 minutes, mice were euthanized by inhalation of CO2.
Biopsies of the injected area were taken and Evans blue eluted from biopsies by Formamide
(Sigma-Aldrich, St. Louis, MO) overnight at 56˚C. Absorbance of Evans blue was measured at
620 nm using a POLARstar Omega microplate reader (BMG Labtech, Ortenberg, Germany).
In situ hybridization
Detection of CD5-2 in blood vessels was done as previously described [25]. In brief, animals
(P6) were treated with CD5-2 via IP injection. After 6 hours, they underwent intracardiac per-
fusion with PBS. Hindbrains were then dissected and kept in 20% sucrose overnight. The hind-
brain was cut into 10-μm sections. The probe for hybridization was target specific for CD5-2
(50-FAM-IT mG mA mA IG mC mA mA IC mU mG IT mG mA IA-30). Hybridization tem-
perature cycle and fluorescence detection was the same as the one used previously [25]. After
washes and subsequent staining with anti-CD31, we found the normal dilutions of 1:200
required for routine CD31 staining did not work. CD31 staining was weakly detectable even
after we used a dilution of 1:50, thus suggesting that there has been a decrease in signal, likely
because of the time and manner of sample preparation. Alternatively, the identification of vas-
culature in the brain sections was aided by the autofluorescence or native fluorescence of elas-
tin fibers within the vasculature. This is widely reported across different tissues and can be
detected at wavelengths similar to FITC [82, 83]. Using the native fluorescence as a guide, we
could pinpoint the localization of CD5-2 to the brain vasculature.
Histology and immunofluorescence
Dissected hindbrains were fixed in 4% PFA at 4˚C for 2–3 hours, then incubated in 30%
sucrose (Sigma-Aldrich, St. Louis, MO) for overnight. Tissues were then frozen in Tissue-Tek
O.C.T. Compound (Sakura Finetek, Torrance, CA) and after freezing, 10-μm sections of hind-
brain tissue were cut onto Superfrost Plus slides (Thermo Fisher Scientific, Waltham, MA).
The sections from littermate control and experimental animal sections were placed on the
same slide and immunostained at the same time under identical conditions using our standard
protocol [25]. For primary staining, the following antibodies were used for immunostaining:
rat CD31 (1:200, 553370, BD Biosciences, San Jose, CA), rabbit ICAM-1 (1:200, ab124759,
Abcam,Cambridge, United Kingdom), rabbit pMLC2 (1:200, 3674S, Cell Signaling Technol-
ogy, Danvers, MA), rat CD144 (1:200, 555289, BD Biosciences, San Jose, CA), goat VE-
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cadherin (1:1,000, sc-6458, Santa Cruz Biotechnology, Dallas, TX), and rat CD11b (1:200, 53-
0112-82, eBiosciences, San Diego, CA). Secondary antibodies were as follows: anti-rabbit
Alexa Fluor 594, anti-Donkey Alexa Fluor 488, anti-rat Alexa Fluor 488, or anti-rat Alexa
Fluor 647 antibodies (1:600; Thermo Fisher Scientific, Waltham, MA) in PBS. Cell nuclei were
stained with DAPI. Images were taken by SP5 confocal microscope (Leica Biosystems, Wetzlar,
Germany) using the same parameters and were subsequently overlaid using Fiji imageJ soft-
ware (version 2.2.2-rc-34/1.50a, National Institutes of Health). To quantify VE-cadherin, cells
immunostained for VE-cadherin were converted to black and white based on the same thresh-
old between TSB control- and CD5-2–treated mice, and VE-cadherin expression intensity was
defined as the mean number of pixels above the threshold in the area lining the CCM lesions.
SEM
The structures of endothelium of CCM animal were analyzed by SEM as previously reported,
with modification [84]. In brief, animals were treated with TSB control or CD5-2 at P6 and P8.
At P12, animals were euthanized by inhalation of CO2, followed by intracardiac perfusion with
fixative (pH 7.4, 15 mL per animal) containing 0.25% (w/v) glutaraldehyde (ProSciTech,
Queensland, Australia) EM grade, 2% paraformaldhyde (Sigma-Aldrich, St. Louis, MO), 20
mmol/L calcium chloride (Ajax Chemicals, New South Wales, Australia), 2% (w/v) sucrose
(Sigma-Aldrich, St. Louis, MO), and 0.1 mol/L cacodylate (ProSciTech, Queensland, Austra-
lia). Hindbrains were then dissected and kept in fixative overnight before being analyzed by a
JEOL 6340 SEM, as previously described [84] (SEMTech Solutions, MA).
X-ray microCT-based quantification of CCM lesions
X-ray microCTs were employed to quantify CCM lesions, as previously reported [8]. In brief,
after fixation in 4% formaldehyde, hindbrains were then detached from mid/forebrains and
soaked for 48 hours in 2% osmium tetroxide solution (Sigma-Aldrich, St. Louis, MO) and
washed several times with water before being scanned by using Xradia MicroCT system (Xra-
dia MicroXCT-400, ZEISS, Oberkochen, Germany). The raw images were continuously
scanned 2D stacks. Images where then processed by 3D image processing software Avizo (ver-
sion 9.3.0, FEI Visualization Sciences Group, Hillsboro, OR). Lesions were identified by their
lower grayscale intensity and the shape of the feature, together with the “Magic Wand” func-
tion from Avizo, which is able to localize the labelled individual lesions across multiple cross
sections. These stacks were then reconstructed to 3D by using Avizo. Finally, hindbrain image
was overlaid with the labeled lesions in Avizo to attain the desired spatially significant view.
The volume of hindbrain and individual lesions were automatically measured with the
software.
Neutrophil adhesion assay
The live-cell microscopy flow model has been described [85]. In brief, human polymorphonu-
clear neutrophils (PMNs) were isolated from blood by 20% dextran (1:1) sedimentation at
room temperature for 40 minutes. HUVECs treated with control and CD5-2 were plated onto
the μ-Slide I Luer (Ibidi, Planegg, Germany) to grow to confluence. EC monolayers were then
stimulated with 5 ng/mL TNF-α (R&D system, Minneapolis, MN) for 4 hours prior to shear
stress treatment. The neutrophils in HUVEC medium (106 cells/mL) were added into the ibidi
pump system (Ibidi, Planegg, Germany). The dynamic adhesion of neutrophils onto control or
CD5-2–treated HUVECs was recorded after 6 minutes of rolling (2 dyn/cm2 constant shear
stress) using an inverted phase-contrast microscope (Nikon Eclipse TE2000, Nikon,Tokyo,
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Japan) connected to a Nikon Digital Sight camera. Neutrophils per field were counted by Fiji
ImageJ software (version 2.2.2-rc-34/1.50a, National Institutes of Health).
Live cell fluorescent imaging of neutrophil transmigration
The live-cell fluorescent imaging of neutrophil transmigration was recorded using laser scan-
ning confocal microscopy (Leica TCS SP5, Leica Biosystems, Wetzlar, Germany). In brief,
HUVECs treated with control or CD5-2 for 48 hours were plated into the ibidi Culture-Insert
2 Well in the 35-mm petri dish (MatTek, Emu Plains NSW 2750) to form the EC monolayer.
The isolated PMN labeled with CellTracker green dye (Thermo Fisher Scientific, Waltham,
MA) were added onto the top of TNF-α–stimulated HUVECs, which were stained with VE-
cadherin antibody (Cell Signaling Technology, Danvers, MA). The transmigration processes
of PMN across the endothelium treated with control and CD5-2 were recorded by time-lapse
confocal microscopy for 1 hour.
RNA-seq and GSEA
The RNA-seq was done as previously described [85]. Total RNAs were extracted from
HUVEC or VE-cadherin null ECs treated with control or CD5-2 using RNeasy Plus Mini Kit
(Qiagen, Hilden, Germany). A total of 3–5 biological replicates were pooled for RNA-seq.
Libraries were prepared using the NEBNext UltraTM RNA Library Prep Kit for Illumina (San
Diego, CA). After library construction, libraries were diluted to 1.5 ng/uL with the preliminary
quantitative result by Qubit2.0. Library fragments were purified with AMPure XP system
(Beckman Coulter, Brea, CA) and assessed by the Agilent Bioanalyzer 2100 system to detect
the insert size. Library preparations were sequenced on an Illumina Hiseq 4000 platform and
150-bp paired-end reads were generated. Reference genome and gene model annotation files
were downloaded from the genome website browser (NCBI/UCSC/Ensembl) directly. Indexes
of the reference genome were built using Bowtie (v2.2.3), and paired-end clean reads were
aligned to the reference genome using (v2.0.12). We then used HTSeq (v0.6.1) to count the
read numbers mapped of each gene and used fragments per kilo bases per million reads
(FPKM) to estimate gene expression level based on the length of the gene and reads count
mapped to that gene. Prior to differential gene expression analysis, for each sequenced library,
the read counts were adjusted by using a weighted trimmed mean of the log expression ratios
(trimmed mean of M values) [86]. DEGs were then determined using DESeq R package
(v1.12.0). The resulting P values were adjusted using Benjamini and Hochberg’s approach for
controlling the FDR. Genes with an adjusted P value < 0.05 and FDR < 0.005 were assigned as
differentially expressed. Modified GSEA was used to assess functional significance at the level
of sets of genes, as previously described [87]. Heatmaps were generated using the Multiple
Array Viewer MeV_4_8 (version 10.2).
Statistics
All mice were randomized before the treatment. Results of scanning electron microscopy were
assessed blindly. Hindbrain samples were scanned by microCT blindly. All other experiments
were not assessed blindly. Sample size determination was based on previous experience with
similar studies. The researchers were not blinded to the distribution of treatment groups when
performing experiments and data assessment. Data are expressed as mean ± SEM for the indi-
cated number of observations. P values were calculated as indicated in figure legends using an
unpaired, two-tailed Student t test or one-way ANOVA with Tukey correction for multiple
comparisons. P< 0.05 was considered significant.
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Supporting information
S1 Fig. CCM-deficient mice show abnormality in retina and brain vasculature. (A) Mouse
retinas after dissection (i) and (ii) isolectin-B4 (red) and VE-cadherin (green) staining. Bar,
upper panel, 200 μm; lower panel, 100 μm. (B) CCM malformations show blood-filled caverns
in the hindbrain of P12 Ccm2ECKO (iECre, Ccm2fl/fl) mice upon dissection. (ii) Staining of VE-
cadherin in the CCM lesions of different sizes. Bar, (i) 1 mm; (ii) 8 μm. For the raw data used
for quantification, see S1 Fig in S1 Data. CCM, cerebral cavernous malformation; V, vein; VE-
cadherin, vascular endothelial cadherin
(TIF)
S2 Fig. Loss of CCM1 or CCM2 disrupts EC junctions. (A) Real-time PCR analysis of CCM1
or CCM2 expression in HUVECs and hCMEC/D3 treated with siRNA targeting scramble (si-
Ctrl), CCM1 (si-CCM1), or CCM2 (si-CCM2) (n = 2–4). (B) VE-cadherin and claudin-5 pro-
tein expression, analyzed by western blot, in hCMEC/D3 treated with siRNA to Ctrl, CCM1,
or CCM2 (n = 2–3). (C) Immunostaining for VE-cadherin in HUVECs treated with control,
CCM1, or CCM2 siRNAs. Representative images are shown. Bar, upper panel 100 μm; lower
panel 50 μm. (D) miR-27a expression in brain ECs isolated at P5 from the WT (n = 2) and
Ccm2ECKO (n = 3) mice. For the raw data used for quantification, see S2 Fig in S1 Data. CCM,
cerebral cavernous malformation; EC, endothelial cell; hCMEC/D3, human cerebral microvas-
cular endothelial cells/D3; HUVEC, human umbilical vein endothelial cell; miR-27a, micro-
RNA-27a; siRNA, small interfering RNA; VE-cadherin, vascular endothelial cadherin; WT,
wild-type
(TIF)
S3 Fig. CD5-2, a TSB to miR-27a/VE-cadherin, rescues key junction molecule expression.
(A) Sequence of TSB control (Ctrl), CD5-2, miR-27a, and binding site on VE-cadherin 30
UTR. TSBs were modified oligonucleotides. (B) Western blot analysis of VE-cadherin and
claudin-5 in hCMEC/D3 treated with 10 nM siRNAs for scramble control (Ctrl), CCM1, or
CCM2 for 4 hours, followed by transfection of 15 nM CD5-2 or controls, then cultured over-
night. Molecular weights in kilodaltons are shown. Representative blots are shown (n = 3–5),
with α-tubulin used as loading control. For the raw data used for quantification, see S3 Fig in
S1 Data. S3B Fig in S1 Raw images. CCM, cerebral cavernous malformation; hCMEC/D3,
human cerebral microvascular endothelial cells/D3; miR-27a, microRNA-27a; siRNA, small
interfering RNA; TSB, target site blocker; VE-cadherin, vascular endothelial cadherin
(TIF)
S4 Fig. CD5-2 rescues endothelial junction and inhibits CCM lesions in the animal with
CCM diseases. (A) Experimental protocol for early stage treatment was as follows: Ctrl or
CD5-2 (30 mg/kg) was administered by IP injection at P6 and P8, and brains and retinas were
dissected at P12. (B) (i) ZO-1 staining in normal brain vessels from WT mice. (ii) CD5-2
increased ZO-1 expression in CCM lesions. Bar, 60 μm. (C) Representative HE staining of cer-
ebellar sections from Ccm2ECKO mice after treatment with Ctrl or CD5-2. Bar, 100 μm. (D)
Representative image of CD31 staining in cerebellar sections from Ccm2ECKO mice after treat-
ment with Ctrl or CD5-2. Bar, 60 μm. CCM, cerebral cavernous malformation; Ctrl, control;
HE, hematoxylin–eosin; IP, intraperitoneal; siRNA, small interfering RNA; WT, wild-type;
ZO-1, zonula occludens-1
(TIF)
S5 Fig. Late treatment of CD5-2 does not affect CCM lesion numbers. (A) Experimental
protocol for late stage treatment: Ctrl or CD5-2 (30 mg/kg) was administered by IP injection
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at P12 and P14, and brains and retinas were dissected at P19. (B) Number of lesions from mice
treated in (A) (n = 3, from 3 litters). Values are shown as mean ± SEM. N.S, not significant,
determined by Student t test. For the raw data used for quantification, see S5 Fig in S1 Data.
CCM, cerebral cavernous malformation; Ctrl, control; IP, intraperitoneal
(TIF)
S6 Fig. Treatment of CD5-2 has no effect on development and vascularization of hindbrain
and the surface of the retina. (A) Representative images of hindbrain, retina, and their vascu-
lature from Ctrl- and CD5-2–treated WT mice. Bars, brain, 1 mm; retina, 200 μm; bottom
panel left, 100 μm; right, 200 μm. Samples were dissected at P12. (B) Treatment of CD5-2 has
no effect on size of hindbrain from mice treated at P6 and P8; n = 7 mice for control-treated
group and n = 9 mice for CD5-2–treated group. Mice are from 4 different litters. (C) Treat-
ment of CD5-2 has no effect on size of hindbrain from mice treated at P12 and P14 compared
with Ctrl-treated mice (n = 4, from 4 litters). Values are shown as mean ± SEM. N.S, not signif-
icant, determined by Student t test. For the raw data used for quantification, see S6 Fig in S1
Data. CCM, cerebral cavernous malformation; Ctrl, control; WT, wild-type
(TIF)
S7 Fig. CD5-2 rescues defect in dermal integrity in Ccm1 heterozygous mice. (A) Miles
assay of dermal permeability in heterozygous Ccm1 (Tie2-Cre, Ccm1 fl/+) mice in response to
PBS or VEGF after pretreatment with Ctrl or CD5-2. (B) Quantification of Evans blue extrava-
sation, three mice for each group. Bar, 500 μm. Values are shown as mean ± SEM. �P< 0.05,
determined by one-way ANOVA with Tukey correction. For the raw data used for quantifica-
tion, see S7 Fig in S1 Data. CCM, cerebral cavernous malformation; Ctrl, control; VEGF, vas-
cular endothelial growth factor.
(TIF)
S8 Fig. CD5-2 inhibits loss-of-CCM induced RhoA-ROCK activity but has no effect on
KLF2/4 expression. HUVECs were treated with 10 nM siRNAs for scramble control, CCM1,
or CCM2 (si-Ctrl, si-CCM1, or si-CCM2) for 4 hours, followed by transfection of 15 nM CD5-
2 or Ctrl, then cultured for 48 hours. (A) RhoA activity was measured using RhoA G-LISA
activation assay kit (n = 4). (B) Immunostaining was performed to measure pMLC. Represen-
tative images are shown. Intensity of staining was quantified from 3–5 images per treatment,
n = 3 experiments. Bar, 60 μm. Quantification of immunoblots was by Fiji ImageJ software
(n = 3–5). (C) mRNA levels of KLF2 and KLF4 following Ctrl or CD5-2 treatment in CCM1-
or CCM2-depleted ECs, analyzed by real-time PCR analysis (n = 2). Data represent
mean ± SEM. �P< 0.05, ��P< 0.01, ����P< 0.001, determined by one-way ANOVA with
Tukey correction. For the raw data used for quantification, see S8 Fig in S1 Data. CCM, cere-
bral cavernous malformation; Ctrl, control; EC, endothelial cell; G-LISA, G protein linked
immunosorbent assay; HUVEC, human umbilical vein endothelial cell; KLF2/4, kruppel-like
factor 2/4; pMLC, phospho-myosin light chain; RhoA, ras homologue A; ROCK, Rho-associ-
ated protein kinase; siRNA, small interfering RNA
(TIF)
S9 Fig. CD5-2 rescues inflammatory response. (A) CD11b+ (yellow) leukocytes accumulate
in CCM lesions treated with CD5-2. Blood vessels are stained with CD31 (red), and cell nuclei
are stained with DAPI (blue). Images in all panels are representative of at least 3 mice in each
group. Quantification of number of CD11b+ cells in CCM lesion. (B) Quantification of num-
ber of CD11b+Gr1hi cells in MC38 tumor model (n = 8). (C) Quantification of percentage of
transmigrated neutrophils (%) across the control- and CD5-2–treated ECs in the transwell
migration assay (n = 3). For the raw data used for quantification, see S9 Fig in S1 Data. CCM,
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cerebral cavernous malformation; EC, endothelial cell
(TIF)
S10 Fig. CD5-2 has no effect on gene expression profile in VE-cadherin null ECs. Heatmap
of all genes between Ctrl- and CD5-2–treated VE-cadherin null ECs (VE-cadherin−/−). Ctrl,
control; EC, endothelial cell; HUVEC, human umbilical vein endothelial cell; VE-cadherin,
vascular endothelial cadherin
(TIF)
S1 Movie. CD5-2 inhibits neutrophils adhesion on EC monolayer. Dynamic adhesion of
neutrophils onto TNF-α–stimulated EC monolayer treated with control and CD5-2. HUVECs
treated with control and CD5-2 were plated onto the μ-Slide I Luer (Ibidi, Germany). The neu-
trophils in HUVEC medium were added into the ibidi pump system (Ibidi, Germany). The
dynamic adhesion of neutrophils onto control- or CD5-2–treated HUVECs was recorded
under an inverted phase-contrast microscope after 6 minutes of rolling. EC, endothelial cell;
HUVEC, human umbilical vein endothelial cell; TNF-α, tumor necrosis factor-α
(PPTX)
S2 Movie. CD5-2 inhibits neutrophil transendothelial migration. Paracellular transmigra-
tion of GFP-labeled neutrophils (green) through TNF-α–stimulated endothelium (VE-Cad-
herin, red) in the presence of control and CD5-2 in vitro. The majority of neutrophils treated
with control transmigrated via the paracellular route, as assessed in real time, by contact and
passage through the area bonded by VE-cadherin (red), whereas CD5-2 inhibited neutrophil
transmigration. GFP, green fluorescent protein; TNF-α, tumor necrosis factor α; VE-cadherin,
vascular endothelial cadherin
(PPTX)
S1 Data. Quantitation for all main and supporting figures: Figs 1, 2, 3, 4, 5, 6, S2, S3, S5,
S6, S7, S8, S9 and S10. Additional information about a particular panel in a figure is included.
(XLSX)
S1 Raw images. Original immunoblot gel images for Figs 6 and S3.
(PPTX)
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